178 completed, 20 terminated, 15 unknown, 13 recruiting. 151 Not applicable, 38 Phase 2, 16 Phase 1, 16 Phase 4, 14 Phase 3.
Follow Opioid-use Disorder: new trials by email Literature Review of Opioid-use Disorder trials Research Report on Opioid-use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| fNIRs-based Neurofeedback to Reduce Relapse in pOUD/AUD fNIRs-based Neurofeedback, Sham feedback - Alcohol Use Disorder, Alcoholism | Not applicable | Withdrawn | Milton S. Hershey Medical Center | 2026-01-01 | 2024-12-20 | |
| Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder ED-Initiated treatment with buprenorphine / naloxone - Opioid-use Disorder | Phase 2 | Withdrawn | University of California, Davis | 2025-07-30 | 2024-11-12 | |
| Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women Mobile-based NAS Caregiving Tool - Neonatal Abstinence Syndrome, Opioid-use Disorder | Not applicable | Active not recruiting | Washington State University | 30 | 2024-07-15 | 2026-02-05 |
| Social Networks and Methadone Maintenance Treatment Retention and Antiretroviral Therapy Retention in Tanzania Supportive care through community support persons - Opioid-use Disorder, Adherence, Medication | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 58 | 2024-03-01 | 2025-10-08 |
| Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder Accelerated intermittent theta-burst stimulation (aiTBS) - Opiate Dependence, Suicidal Ideation | Not applicable | Withdrawn | Stanford University | 2024-01-01 | 2024-07-16 | |
| Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder Buprenorphine/naloxone, Placebo - Opioid-use Disorder | Phase 2 / Phase 3 | Recruiting | New York State Psychiatric Institute | 180 | 2023-04-18 | 2026-05-19 |
| Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use Placebo oral tablet, Yohimbine + Hydrocortisone, sham rTMS - Stress, Opioid-use Disorder | Phase 2 | Withdrawn | Wayne State University | 2023-04-10 | 2023-04-13 | |
| Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment Acceptance and commitment therapy, Valera Smartphone Application, Treatment as Usual - Opioid-use Disorder, Chronic Pain | Not applicable | Active not recruiting | Albert Einstein College of Medicine | 125 | 2023-02-02 | 2026-07-15 |
| Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 Methadone, Buprenorphine/naloxone, XR-Naltrexone - Opioid-use Disorder, HIV-1-infection | Phase 2 | Terminated | University of Pennsylvania | 78 | 2023-01-30 | 2026-04-07 |
| Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose Opioid-Use Disorder, Opioid Overdose | Unknown | BC Centre on Substance Use | 40 | 2022-10-17 | 2022-11-17 | |
| Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization BUP microdose induction, TAU, Linkage to outpatient BUP treatment - Substance Use Disorders, Opioid-use Disorder | Phase 4 | Terminated | Montefiore Medical Center | 23 | 2022-09-29 | 2026-05-08 |
| Competitive Revision for CLARO: Collaboration Leading to Addiction Treatment and Recovery From Other Stresses Collaborative care Plus - Opioid-use Disorder, Addiction | Not applicable | Completed | RAND | 68 | 2022-08-31 | 2024-08-09 |
| Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder INDV-2000, Placebo, SUBOXONE® sublingual film - Healthy Volunteer, Opioid-use Disorder | Phase 1 | Completed | Indivior Inc. | 64 | 2022-08-17 | 2024-08-21 |
| Cariprazine for Comorbid Cocaine and Opioid Use Disorder Cariprazine 1.5 MG, Placebo - Opioid-use Disorder, Cocaine Use Disorder | Phase 2 | Completed | Kyle Kampman | 26 | 2022-08-05 | 2026-01-23 |
| Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections BICX104, Vivitrol - Opioid-use Disorder | Phase 1 | Completed | BioCorRx Inc | 24 | 2022-06-17 | 2023-08-16 |
| Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone - Opioid-use Disorder, Opioid Withdrawal | Not applicable | Completed | Spark Biomedical, Inc. | 108 | 2022-05-27 | 2025-07-04 |
| Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder Cannabidiol (CBD) 600 mg, Placebo - Opioid-use Disorder | Phase 2 | Completed | University of California, Los Angeles | 35 | 2022-05-19 | 2026-04-22 |
| Mindful Moms in Recovery Mindful Moms Yoga Mindfulness Intervention - Opioid-use Disorder | Not applicable | Completed | Trustees of Dartmouth College | 4 | 2022-05-01 | 2025-07-31 |
| Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia Enhanced usual care (EUC), Peer-based counseling - HIV Seropositivity, Opioid-use Disorder | Not applicable | Terminated | Yale University | 2 | 2022-04-26 | 2026-06-29 |
| Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder Cannabidiol 100 MG/ML [Epidiolex], Placebo - Opioid-use Disorder | Phase 2 | Completed | Brigham and Women's Hospital | 15 | 2022-04-14 | 2023-10-05 |
Showing 20 of 249. Sign in to see all of them.
Opioid-Related Disorders (249) · Substance-Related Disorders (31) · Chronic Pain (14) · Behavior, Addictive (13) · Depression (11) · Alcoholism (8) · Anxiety Disorders (8) · Stress Disorders, Post-Traumatic (8) · HIV Infections (6) · Hepatitis C (6) · Opiate Overdose (6) · Acquired Immunodeficiency Syndrome (5) · Pain (5) · Drug Overdose (4) · Medication Adherence (4)
Narcotic-Related Disorders (249) · Chemically-Induced Disorders (248) · Mental Disorders (245) · Substance-Related Disorders (218) · Behavior (46) · Pathological Conditions, Signs and Symptoms (26) · Neurologic Manifestations (19) · Signs and Symptoms (19) · Infections (18) · RNA Virus Infections (17) · Blood-Borne Infections (16) · Communicable Diseases (16) · Virus Diseases (16) · Behavioral Symptoms (13) · Compulsive Behavior (13)
Buprenorphine (18) · Buprenorphine, Naloxone Drug Combination (18) · vivitrol (10) · Therapeutics (8) · Naltrexone (6) · Sublocade (5) · Naloxone (4) · lofexidine (4) · Cannabidiol (3) · Oxycodone (3) · Standard of Care (3) · Transcranial Magnetic Stimulation (3) · Case Management (2) · Dosage Forms (2) · Exercise (2)
New York State Psychiatric Institute (14) · Yale University (11) · NYU Langone Health (7) · Brigham and Women's Hospital (5) · Friends Research Institute, Inc. (5) · Indivior Inc. (5) · Johns Hopkins University (5) · University of Pennsylvania (5) · University of Washington (5) · HealthPartners Institute (4) · Massachusetts General Hospital (4) · University of California, Los Angeles (4) · University of Minnesota (4) · University of Pittsburgh (4) · University of Vermont (4)
United States (221) · Vietnam (4) · Canada (3) · Norway (2) · Ukraine (2) · Australia (1) · France (1) · Kyrgyzstan (1) · Malaysia (1) · Moldova (1) · Sweden (1) · Tanzania (1) · United Kingdom (1)
Zev Schuman-Olivier, MD (5) · Ezra Golberstein, PhD (3) · Adam Bisaga, MD (2) · Allison J Ober, PhD (2) · Aurora Quaye, MD (2) · Grace Lim, MD, MS (2) · Itai Danovitch, MD (2) · Karen J Derefinko, PhD (2) · Kathleen Moore, PhD (2) · Kenneth Silverman, Ph.D. (2) · Mark Greenwald, PhD (2) · Miriam Komaromy (2) · Navid Khodaparast, PhD (2) · Ryan McCormack, MD (2) · Sandra D Comer, PhD (2)
PMID 40342086, PMID 35395811, PMID 41460640, PMID 12738348, PMID 12954743, PMID 18559110, PMID 21270789, PMID 23531704, PMID 23617867, PMID 24977636, PMID 25022635, PMID 25569005, PMID 26432420, PMID 27687214, PMID 27799240, PMID 28068780, PMID 28669739, PMID 28742676, PMID 28890331, PMID 29141653, PMID 29226017, PMID 29473258, PMID 30396797, PMID 31088887, PMID 31152039, PMID 31174929, PMID 31342057, PMID 31446893, PMID 32187112, PMID 32293514, PMID 32309637, PMID 32833482, PMID 33129355, PMID 33413493, PMID 33517894, PMID 33631356, PMID 33750454, PMID 33789642, PMID 33819055, PMID 33856360, PMID 33962675, PMID 34130758, PMID 34286886, PMID 34301246, PMID 34323526, PMID 34447323, PMID 34635178, PMID 34663379, PMID 34717736, PMID 34737091
R33DA046084 (3), R33AT010125 (2), R42DA050398 (2), R61AT010604 (2), U01DA046910 (2), UG1DA040314 (2), 1RM1DA055437-01 (1), 1UF1MH121944-01 (1), 1UF1MH121954 (1), 1UG1DA049435 (1), 1UG1DA050069 (1), 1UG3DA048743-01 (1), 1UG3DA051241-01 (1), 1UL1TR001430 (1), 2017 (1)